Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies Stock Popped Today

By Prosper Junior Bakiny - Updated Jan 15, 2021 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.

What happened

Shares of DBV Technologies (DBVT 0.00%), a clinical-stage biotech company based in France, are soaring on Friday and are up by 41.2% as of 11:34 a.m. EST after rising by as much as 49.7% earlier in the day. The catalyst for these gains is a regulatory update the company provided regarding its potential treatment for peanut allergy, Viaskin Peanut. 

So what

Viaskin Peanut is a patch that can desensitize patients' immune systems by exposing them to peanut protein. But due to concerns over the effect of patch adhesion on its efficacy, the U.S. Food and Drug Administration (FDA) did not approve Viaskin Peanut. In October, DBV Technologies requested a Type A meeting with the regulatory authority to discuss a path forward. Type A meetings are used to resolve issues that have stalled the development of a drug.

Man holding a sign that says "FDA Approved."

Image source: Getty Images.

On Thursday evening, DBV Technologies said that the feedback it received from the FDA at this meeting "provides a well-defined regulatory path forward" for Viaskin Peanut. Specifically, the company opted to create a modified Viaskin Peanut patch, which will not be considered a new product entity. The FDA recommended that DBV Technologies conduct a safety and adhesion trial to assess the modified Viaskin Peanut patch. The company said it would submit the protocol of this study to the FDA for review in the second quarter before starting the trial.

Now what

There is still a long road ahead for DBV Technologies and Viaskin Peanut in the U.S., but the agreement it reached with the FDA is a much better option than having to scrap the program altogether. Also, in November, the biotech company announced it had submitted Viaskin Peanut for approval in Europe. If all goes well for the company, its peanut allergy treatment could hit the market both in the U.S. and in Europe within the next couple of years or so. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
$2.50 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.